Mesalazine mainly acts locally in the intestinal mucosa rather than producing significant systemic effects. In inflammatory bowel disease, the production of arachidonic acid metabolites, including prostaglandins and leukotrienes, is increased. Mesalazine helps reduce intestinal inflammation by inhibiting cyclooxygenase activity and decreasing prostaglandin production in the colon.
Using Mesalazine together with other potentially nephrotoxic medicines, such as NSAIDs or azathioprine, may increase the risk of kidney-related adverse effects.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Tablet – Mild to Moderate Ulcerative Colitis
Adults:
The usual recommended dose is 800 mg (two 400 mg tablets) three times daily for 6 weeks. If required, the total daily dose may be increased to 4.8 g/day, given in divided doses.
Children aged 5 years and above:
Maintenance of remission in mild to moderate ulcerative colitis:
Adults generally take 1.6 g/day, divided into 2–4 doses. When necessary, the dose may be increased to 2.4 g/day in divided doses.
Maintenance of Crohn’s disease:
Ulcerative Colitis – Adults:
Children 6 years and older:
For children weighing up to 40 kg, approximately half the adult dose may generally be used, while children above 40 kg may receive the usual adult dose.
Elderly: Patients aged 65 years or older require careful monitoring, as reduced kidney function is more common in this age group. Renal function should be assessed before treatment, and blood cell counts should be monitored during therapy.
Pediatric: Safety and effectiveness have not been fully established according to the provided information.
The granules should not be chewed. Empty the sachet directly onto the tongue and swallow with water or orange juice. Alternatively, the granules may be mixed with yogurt and consumed immediately.
Mesalazine should be used during pregnancy only when the expected benefit outweighs the potential risk to the fetus. Caution is advised when administering it to breastfeeding mothers.
Patients with pyloric stenosis may experience prolonged retention of Mesalazine tablets in the stomach, which can delay the release of the medicine in the colon.
Mesalazine has been associated with kidney problems, including minimal change nephropathy and acute or chronic interstitial nephritis. Therefore, patients with existing kidney disease or impaired renal function should use it cautiously. Kidney function should be assessed before treatment and monitored periodically.
Cases of liver failure have been reported in patients with pre-existing liver disease. Extra caution is therefore required in patients with hepatic impairment.
Store below 30°C, protected from light and moisture. Keep out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.